At a glance
- Originator AEterna Zentaris Inc
- Class Anthracyclines; Antineoplastics; Pyrroles
- Mechanism of Action DNA intercalators; Somatostatin receptor agonists; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 06 Oct 2008 Discontinued - Preclinical for Solid tumours in USA (IV)
- 01 Jun 2006 This compound is still in active development
- 30 Dec 2002 Zentaris has been acquired by AEterna Laboratories